The highest level of efficacy observed in these studies was seen among patients with low-grade CNS tumors [65,66] or in cases with recurrent ependymoma and anaplastic ependymomas harbouring VEGF overexpression [67]. This evidence concerns the gene VEGFA and central nervous system neoplasm.